drugset / Trial / NCT02265510
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This was a study of INCB052793 given to patients with advanced malignancies that was to be conducted in three phases; Phase 1a (Monotherapy) and Phase 1b (Combination Therapy) and Phase 2 (Combination therapy of INCB052793 with azacitidine and itacitinib with azacitidine). Phase 1 had two parts; a dose escalation (Part 1) and an expansion (Part 2).
Timeline
- Start
- 2014-09-10
- Primary completion
- 2019-02-27
- Completion
- 2019-02-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INCB052793 | Unknown | — | Oral |
| Background | Azacitidine | Other / unclassified | — | Subcutaneous |
| Background | Bortezomib | Small molecule | — | Intravenous |
| Background | Carfilzomib | Other / unclassified | — | Intravenous |
| Background | Dexamethasone | Small molecule | — | Oral |
| Background | Gemcitabine | Small molecule | — | Intravenous |
| Background | Itacitinib | Small molecule | — | Oral |
| Background | Lenalidomide | Other / unclassified | — | Oral |
| Background | Nab-paclitaxel | Small molecule | — | Intravenous |
| Background | Parsaclisib | Unknown | — | Oral |
| Background | Pomalidomide | Other / unclassified | — | Oral |